TABLE 2.
Summary of NONMEM model executions
| Covariate model (label) | Pharmacokinetic parameter evaluated | NONMEM model parameters | Change in objective functiona |
|---|---|---|---|
| Combination therapy (COMB)b | Clearance | CL = Θ1*(1 − COMB) + Θ2*(COMB) | −3.214 |
| V = Θ3 | |||
| Ka = CL/V + Θ4 | |||
| Combination therapy (COMB)b | Volume of distribution | CL = Θ1 | −0.010 |
| V = Θ2*(1 − COMB) + Θ3*(COMB) | |||
| Ka = CL/V + Θ4 | |||
| Dose (DOSE)c | Clearance | CL = Θ1*(DOSE/300)**Θ2 | −0.510 |
| V = Θ3 | |||
| Ka = CL/V + Θ4 | |||
| Dose (DOSE)c | Volume of distribution | CL = Θ1 | −2.159 |
| V = Θ2*(DOSE/300)**Θ3 | |||
| Ka = CL/V + Θ4 | |||
| Age (AGE)d | Clearance | CL = Θ1*(AGE/39)**Θ2 | −8.555 |
| V = Θ3 | |||
| Ka = CL/V + Θ4 | |||
| Age (AGE)d | Volume of distribution | CL = Θ1 | −3.595 |
| V = Θ2*(AGE/39)**Θ3 | |||
| Ka = CL/V + Θ4 | |||
| Gender (SEX)e | Clearance | CL = Θ1*(1 − SEX) + Θ2*(SEX) | −0.022 |
| V = Θ3 | |||
| Ka = CL/V + Θ4 | |||
| Gender (SEX)e | Volume of distribution | CL = Θ1 | −4.505 |
| V = Θ2*(1 − SEX) + Θ3*(SEX) | |||
| Ka = CL/V + Θ4 | |||
| Weight (WT)f | Clearance | CL = Θ1*(WT/74)**Θ2 | −5.312 |
| V = Θ3 | |||
| Ka = CL/V + Θ4 | |||
| Weight (WT)f | Volume of distribution | CL = Θ1 | −0.856 |
| V = Θ2*(WT/74)**Θ3 | |||
| Ka = CL/V + Θ4 |
a
Change in value of objective function from that of the base model.
b
The values of COMB are 0 for monotherapy and 1 for combination antiretroviral therapy.
c
Subject dose expressed as a fraction of the 300-mg dose.
d
Subject age expressed as a fraction of the median age for the population included in the pharmacokinetic analysis (39 years).
e
Values of SEX are 0 for men and 1 for women.
f
Subject weight expressed as a fraction of the median weight for the population included in the pharmacokinetic analysis (74 kg).